JSPR
Jasper Therapeutics, Inc.
Price Chart
Latest Quote
$0.44
-0.05 (-9.74%)
Current Price
| Previous Close | $0.49 |
| Open | $0.49 |
| Day High | $0.52 |
| Day Low | $0.44 |
| Volume | 311,824 |
Stock Information
| Shares Outstanding | 28.01M |
| Total Debt | $757K |
| Cash Equivalents | $14.14M |
| Net Income | $-55.73M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $12.40M |
| EPS (TTM) | $-2.58 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $-990K |
| Income | $-55.73M |
| Book/sh | $0.12 |
| Cash/sh | $0.50 |
| Employees | 22 |
Financial Ratios
| Quick Ratio | 1.57 |
| Current Ratio | 2.26 |
| Debt/Eq | 22.27 |
Returns & Margins
| ROA | -112.23% |
| ROE | -244.21% |
Ownership
| Insider Ownership | 1.19% |
| Institutional Ownership | 60.52% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -0.17 |
| P/B | 3.66 |
Analyst Data
| Recommendation | buy |
| Target Price | $8.62 |
Technical Indicators
| SMA20 | $0.52 |
| SMA50 | $0.76 |
| SMA200 | $1.49 |
| RSI | 42.46 |
| ATR | 0.0564 |
| Shares Float | 21.88M |
| Short Float | 7.15% |
| Short Ratio | 3.06 |
| Rel Volume | 0.42 |
Performance History
| Week | -5.94% |
| Month | -51.48% |
| Quarter | -59.36% |
| 6 Months | -76.81% |
| YTD | -75.92% |
| Year | -92.05% |
| 3 Years | -96.72% |
| 5 Years | -99.55% |
| 10 Years | -99.55% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-25 | $0.44 | 316,200 |
| 2026-06-24 | $0.49 | 279,300 |
| 2026-06-23 | $0.49 | 650,200 |
| 2026-06-22 | $0.50 | 1,678,700 |
| 2026-06-18 | $0.45 | 286,600 |
| 2026-06-17 | $0.47 | 202,500 |
| 2026-06-16 | $0.45 | 265,300 |
| 2026-06-15 | $0.48 | 509,200 |
| 2026-06-12 | $0.46 | 237,100 |
| 2026-06-11 | $0.47 | 196,800 |
| 2026-06-10 | $0.46 | 320,800 |
| 2026-06-09 | $0.47 | 407,300 |
| 2026-06-08 | $0.47 | 570,400 |
| 2026-06-05 | $0.49 | 558,800 |
| 2026-06-04 | $0.48 | 865,000 |
| 2026-06-03 | $0.53 | 1,639,800 |
| 2026-06-02 | $0.55 | 2,850,900 |
| 2026-06-01 | $0.53 | 2,486,900 |
| 2026-05-29 | $0.83 | 337,900 |
| 2026-05-28 | $0.89 | 230,600 |
| 2026-05-27 | $0.90 | 232,300 |
| 2026-05-26 | $0.91 | 114,600 |
About Jasper Therapeutics, Inc.
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast stem cell driven diseases in the United States. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factors from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma. Jasper Therapeutics, Inc. was founded in 2018 and is headquartered in Redwood City, California.
đ° Latest News
Bears are Losing Control Over Jasper Therapeutics (JSPR), Here's Why It's a 'Buy' Now
Zacks âĸ 2026-06-03T13:55:02Z
Evercore ISI Lowers its Price Target on Jasper Therapeutics (JSPR) to $7
Insider Monkey âĸ 2026-04-07T14:29:32Z
Why UBS Started Jasper Therapeutics (JSPR) at Neutral Despite Progress in Briquilimab
Insider Monkey âĸ 2026-03-29T20:50:45Z
Jasper Therapeutics reports updated data from briquilimab studies
TipRanks âĸ 2026-01-09T12:15:17Z
Companies Like Jasper Therapeutics (NASDAQ:JSPR) Could Be Quite Risky
Simply Wall St. âĸ 2025-11-20T10:13:59Z
Positive Signs As Multiple Insiders Buy Jasper Therapeutics Stock
Simply Wall St. âĸ 2025-10-10T10:24:44Z
Jasper Therapeutics to Halt Asthma Study After Drug Batch Issue; Shares Fall Pre-Bell
MT Newswires âĸ 2025-07-07T13:02:00Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $83,883,000 | $76,239,000 | $68,861,000 | $51,196,000 |
| Other Income Expense | $6,341,000 | $-88,000 | $-803,000 | $12,810,000 |
| Other Non Operating Income Expenses | $-2,187,000 | $-88,000 | $-246,000 | $-115,000 |
| Net Non Operating Interest Income Expense | $1,741,000 | $5,058,000 | $5,199,000 | $701,000 |
| Operating Expense | $83,883,000 | $76,239,000 | $68,861,000 | $51,196,000 |
| General And Administrative Expense | $20,779,000 | $20,418,000 | $17,076,000 | $16,569,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-75,801,000 | $-71,269,000 | $-64,465,000 | $-37,685,000 |
| Net Interest Income | $1,741,000 | $5,058,000 | $5,199,000 | $701,000 |
| Interest Income | $1,741,000 | $5,058,000 | $5,199,000 | $701,000 |
| Normalized Income | $-84,329,000 | $-71,269,000 | $-63,908,000 | $-50,610,000 |
| Net Income From Continuing And Discontinued Operation | $-75,801,000 | $-71,269,000 | $-64,465,000 | $-37,685,000 |
| Total Operating Income As Reported | $-83,883,000 | $-76,239,000 | $-68,861,000 | $-51,196,000 |
| Net Income Common Stockholders | $-75,801,000 | $-71,269,000 | $-64,465,000 | $-37,685,000 |
| Net Income | $-75,801,000 | $-71,269,000 | $-64,465,000 | $-37,685,000 |
| Net Income Including Noncontrolling Interests | $-75,801,000 | $-71,269,000 | $-64,465,000 | $-37,685,000 |
| Net Income Continuous Operations | $-75,801,000 | $-71,269,000 | $-64,465,000 | $-37,685,000 |
| Pretax Income | $-75,801,000 | $-71,269,000 | $-64,465,000 | $-37,685,000 |
| Interest Income Non Operating | $1,741,000 | $5,058,000 | $5,199,000 | $701,000 |
| Operating Income | $-83,883,000 | $-76,239,000 | $-68,861,000 | $-51,196,000 |
| Special Income Charges | - | $0 | $18,000 | $5,725,000 |
| Per Share | ||||
| Diluted EPS | $-3.95 | $-4.89 | $-6.18 | $-10.30 |
| Basic EPS | $-3.95 | $-4.89 | $-6.18 | $-10.30 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-91,355,000 | $-74,866,000 | $-67,196,000 | $-63,146,000 |
| Total Unusual Items | $8,528,000 | $0 | $-557,000 | $12,925,000 |
| Total Unusual Items Excluding Goodwill | $8,528,000 | $0 | $-557,000 | $12,925,000 |
| Reconciled Depreciation | $1,056,000 | $1,373,000 | $1,108,000 | $975,000 |
| EBITDA (Bullshit earnings) | $-82,827,000 | $-74,866,000 | $-67,753,000 | $-50,221,000 |
| EBIT | $-83,883,000 | $-76,239,000 | $-68,861,000 | $-51,196,000 |
| Diluted Average Shares | $19,168,110 | $14,584,870 | $10,439,034 | $3,648,276 |
| Basic Average Shares | $19,168,110 | $14,584,870 | $10,439,034 | $3,648,276 |
| Diluted NI Availto Com Stockholders | $-75,801,000 | $-71,269,000 | $-64,465,000 | $-37,685,000 |
| Gain On Sale Of Security | $8,528,000 | - | $-575,000 | $7,200,000 |
| Research And Development | $63,104,000 | $55,821,000 | $51,785,000 | $34,627,000 |
| Selling General And Administration | $20,779,000 | $20,418,000 | $17,076,000 | $16,569,000 |
| Other Gand A | $20,779,000 | $20,418,000 | $17,076,000 | $16,569,000 |
| Restructuring And Mergern Acquisition | - | $0 | $-18,000 | $-5,725,000 |
Fetched: 2026-06-25
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $4,151,000 | $61,674,000 | $78,440,000 | $35,989,000 |
| Total Assets | $35,779,000 | $79,899,000 | $94,892,000 | $48,361,000 |
| Total Non Current Assets | $1,134,000 | $4,088,000 | $5,954,000 | $6,630,000 |
| Other Non Current Assets | $530,000 | $1,237,000 | $1,760,000 | $1,176,000 |
| Current Assets | $34,645,000 | $75,811,000 | $88,938,000 | $41,731,000 |
| Other Current Assets | $664,000 | $646,000 | $295,000 | $364,000 |
| Prepaid Assets | $5,289,000 | $3,528,000 | $1,506,000 | $2,204,000 |
| Cash Cash Equivalents And Short Term Investments | $28,692,000 | $71,637,000 | $86,887,000 | $38,250,000 |
| Cash And Cash Equivalents | $28,692,000 | $71,637,000 | $86,887,000 | $38,250,000 |
| Receivables | - | $0 | $250,000 | $913,000 |
| Taxes Receivable | - | $0 | $250,000 | $250,000 |
| Other Receivables | - | - | - | $663,000 |
| Debt | ||||
| Total Debt | $1,235,000 | $1,813,000 | $2,786,000 | $3,651,000 |
| Long Term Debt And Capital Lease Obligation | $0 | $724,000 | $1,814,000 | $2,786,000 |
| Current Debt And Capital Lease Obligation | $1,235,000 | $1,089,000 | $972,000 | $865,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $31,628,000 | $18,225,000 | $16,452,000 | $12,372,000 |
| Total Non Current Liabilities Net Minority Interest | $18,428,000 | $2,988,000 | $4,078,000 | $5,307,000 |
| Other Non Current Liabilities | $2,264,000 | $2,264,000 | $2,264,000 | $2,362,000 |
| Derivative Product Liabilities | $16,164,000 | $0 | $0 | $150,000 |
| Current Liabilities | $13,200,000 | $15,237,000 | $12,374,000 | $7,065,000 |
| Other Current Liabilities | $120,000 | $419,000 | $317,000 | $194,000 |
| Payables And Accrued Expenses | $10,256,000 | $10,629,000 | $9,318,000 | $4,419,000 |
| Payables | $6,220,000 | $4,027,000 | $4,149,000 | $1,768,000 |
| Accounts Payable | $6,220,000 | $4,027,000 | $4,149,000 | $1,768,000 |
| Tradeand Other Payables Non Current | - | - | - | $0 |
| Equity | ||||
| Common Stock Equity | $4,151,000 | $61,674,000 | $78,440,000 | $35,989,000 |
| Total Equity Gross Minority Interest | $4,151,000 | $61,674,000 | $78,440,000 | $35,989,000 |
| Stockholders Equity | $4,151,000 | $61,674,000 | $78,440,000 | $35,989,000 |
| Retained Earnings | $-316,670,000 | $-240,869,000 | $-169,600,000 | $-105,135,000 |
| Preferred Securities Outside Stock Equity | - | - | - | - |
| Other | ||||
| Ordinary Shares Number | $27,996,819 | $15,022,122 | $11,163,896 | $3,804,567 |
| Share Issued | $27,996,819 | $15,022,122 | $11,163,896 | $3,804,567 |
| Tangible Book Value | $4,151,000 | $61,674,000 | $78,440,000 | $35,989,000 |
| Invested Capital | $4,151,000 | $61,674,000 | $78,440,000 | $35,989,000 |
| Working Capital | $21,445,000 | $60,574,000 | $76,564,000 | $34,666,000 |
| Capital Lease Obligations | $1,235,000 | $1,813,000 | $2,786,000 | $3,651,000 |
| Total Capitalization | $4,151,000 | $61,674,000 | $78,440,000 | $35,989,000 |
| Additional Paid In Capital | $320,818,000 | $302,541,000 | $248,039,000 | $141,124,000 |
| Capital Stock | $3,000 | $2,000 | $1,000 | $0 |
| Common Stock | $3,000 | $2,000 | $1,000 | $0 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $0 | $724,000 | $1,814,000 | $2,786,000 |
| Current Capital Lease Obligation | $1,235,000 | $1,089,000 | $972,000 | $865,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $1,589,000 | $3,100,000 | $1,767,000 | $1,587,000 |
| Current Accrued Expenses | $4,036,000 | $6,602,000 | $5,169,000 | $2,651,000 |
| Net PPE | $604,000 | $2,851,000 | $4,194,000 | $5,454,000 |
| Accumulated Depreciation | $-4,814,000 | $-3,807,000 | $-2,460,000 | $-1,352,000 |
| Gross PPE | $5,418,000 | $6,658,000 | $6,654,000 | $6,806,000 |
| Leases | $2,711,000 | $2,711,000 | $2,477,000 | $2,477,000 |
| Other Properties | $2,015,000 | $3,025,000 | $3,440,000 | $3,592,000 |
| Machinery Furniture Equipment | $692,000 | $922,000 | $737,000 | $737,000 |
| Properties | $0 | $0 | $0 | $0 |
| Treasury Shares Number | - | - | $0 | - |
| Employee Benefits | - | - | $0 | $9,000 |
| Long Term Provisions | - | - | - | $18,000 |
Fetched: 2026-06-25
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-77,168,000 | $-63,154,000 | $-52,334,000 | $-46,434,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-77,161,000 | $-62,602,000 | $-52,067,000 | $-45,858,000 |
| Cash Flow From Continuing Operating Activities | $-77,161,000 | $-62,602,000 | $-52,067,000 | $-45,858,000 |
| Operating Gains Losses | - | $11,000 | $575,000 | $-7,200,000 |
| Investing Activities | ||||
| Capital Expenditure | $-7,000 | $-552,000 | $-267,000 | $-576,000 |
| Investing Cash Flow | $5,000 | $-532,000 | $-267,000 | $-576,000 |
| Cash Flow From Continuing Investing Activities | $5,000 | $-532,000 | $-267,000 | $-576,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $33,968,000 | $47,195,000 | $101,479,000 | $0 |
| Financing Cash Flow | $34,211,000 | $47,884,000 | $100,971,000 | $55,000 |
| Cash Flow From Continuing Financing Activities | $34,211,000 | $47,884,000 | $100,971,000 | $55,000 |
| Net Common Stock Issuance | $33,968,000 | $47,195,000 | $101,479,000 | $0 |
| Common Stock Issuance | $33,968,000 | $47,195,000 | $101,479,000 | $0 |
| Net Other Financing Charges | - | - | $-960,000 | - |
| Net Preferred Stock Issuance | - | - | - | $0 |
| Preferred Stock Issuance | - | - | - | $0 |
| Other | ||||
| End Cash Position | $29,109,000 | $72,054,000 | $87,304,000 | $38,667,000 |
| Beginning Cash Position | $72,054,000 | $87,304,000 | $38,667,000 | $85,046,000 |
| Changes In Cash | $-42,945,000 | $-15,250,000 | $48,637,000 | $-46,379,000 |
| Proceeds From Stock Option Exercised | $243,000 | $689,000 | $452,000 | $55,000 |
| Net PPE Purchase And Sale | $5,000 | $-532,000 | $-267,000 | $-576,000 |
| Sale Of PPE | $12,000 | $20,000 | $0 | - |
| Purchase Of PPE | $-7,000 | $-552,000 | $-267,000 | $-576,000 |
| Change In Working Capital | $-4,923,000 | $184,000 | $5,103,000 | $-649,000 |
| Change In Other Current Liabilities | $-1,670,000 | $-973,000 | $-945,000 | $1,131,000 |
| Change In Other Current Assets | $707,000 | $523,000 | $-584,000 | $-114,000 |
| Change In Payables And Accrued Expense | $-2,181,000 | $2,757,000 | $5,202,000 | $-1,315,000 |
| Change In Accrued Expense | $-4,374,000 | $2,879,000 | $2,821,000 | $836,000 |
| Change In Payable | $2,193,000 | $-122,000 | $2,381,000 | $-2,151,000 |
| Change In Account Payable | $2,193,000 | $-122,000 | $2,381,000 | $-2,151,000 |
| Change In Prepaid Assets | $-1,779,000 | $-2,123,000 | $767,000 | $312,000 |
| Other Non Cash Items | $-5,318,000 | $491,000 | $401,000 | $-5,390,000 |
| Stock Based Compensation | $6,713,000 | $6,619,000 | $5,211,000 | $4,091,000 |
| Asset Impairment Charge | $1,112,000 | $0 | - | - |
| Depreciation Amortization Depletion | $1,056,000 | $1,373,000 | $1,108,000 | $975,000 |
| Depreciation And Amortization | $1,056,000 | $1,373,000 | $1,108,000 | $975,000 |
| Net Income From Continuing Operations | $-75,801,000 | $-71,269,000 | $-64,465,000 | $-37,685,000 |
| Change In Receivables | - | $0 | $663,000 | $-663,000 |
| Gain Loss On Sale Of PPE | - | $11,000 | $0 | - |
| Gain Loss On Investment Securities | - | - | $575,000 | $-7,200,000 |
Fetched: 2026-06-25